The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction.
about
Pharmacogenetics of erectile dysfunction: navigating into uncharted watersRole of phosphodiesterase-5 inhibitors in heart failure: emerging data and concepts.Effect of ketoconazole on the pharmacokinetics of udenafil in healthy Korean subjects.Endothelial dysfunction, erectile dysfunction and phosphodiesterase 5 inhibitors. An update of the current data and future perspectivesFuture prospects in the treatment of erectile dysfunction: focus on avanafil.Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomicsAvanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction.The effects of screw configuration and polymeric carriers on hot-melt extruded taste-masked formulations incorporated into orally disintegrating tablets.Safety of sildenafil in infants*.Mechanism of endothelial cyto-protective and thrombo-resistance effects of sildenafil, vardenafil and tadalafil in male rabbit.Sildenafil and bosentan plasma concentrations in a human immunodeficiency virus- infected patient with pulmonary arterial hypertension treated with ritonavir-boosted protease inhibitorThe cyclic GMP/protein kinase G pathway as a therapeutic target in head and neck squamous cell carcinomaPhosphodiesterase type 5 inhibitors: back and forward from cardiac indicationsThe role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy.Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?Preclinical pharmacokinetics of TPN729MA, a novel PDE5 inhibitor, and prediction of its human pharmacokinetics using a PBPK model.Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function.The use of phosphodiesterase 5 inhibitors with concomitant medications.Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction.In vitro and in vivo small intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: species differences.Tadalafil for the treatment of pulmonary arterial hypertension.ADMET considerations for phosphodiesterase-5 inhibitors.Avanafil for treatment of erectile dysfunction: review of its potential.PDE5 inhibitors: considerations for preference and long-term adherence.Avanafil for erectile dysfunction in elderly and younger adults: differential pharmacology and clinical utility.The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction.Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors.CYP3A4 genotype is associated with sildenafil concentrations in patients with heart failure with preserved ejection fraction.Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS).Population pharmacokinetic analysis to recommend the optimal dose of udenafil in patients with mild and moderate hepatic impairment.Two Distinct Types of Hypercontractile Esophagus: Classic and Spastic Jackhammer.Erectile Dysfunction Drugs Changed the Protein Expressions and Activities of Drug-Metabolising Enzymes in the Liver of Male Rats.Tadalafil in the treatment of erectile dysfunction.Effect of sildenafil in renal ischemia/reperfusion injury in rats.Substrate-specific pharmacokinetic interaction between endothelin receptor antagonists and phosphodiesterase-5 inhibitors--assembling the clues.Vardenafil-induced relaxation and cyclic nucleotide levels in normal and obstructed rat urinary bladder.Concentration-dependent Sildenafil citrate (Viagra) effects on ROS production, energy status, and human sperm function.The effect of periodontal treatment in improving erectile dysfunction: a randomized controlled trial.Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects.Non-allowed Pharmacologically Active Substances in Physical and Sexual Performance Enhancing Products.
P2860
Q28249515-6FF7F1CE-D77C-48EF-B558-E24BB45C201AQ30575578-1DD856E2-82B6-47D7-8782-47A053F93C6AQ33692838-E97A5A8C-0338-4726-9B7B-C9357F67621CQ34013565-E291803D-7261-4EB8-838A-1E939E913666Q34029414-7A22C8E3-0EA8-48A1-A2D1-B8DB3AA25A62Q34344390-2915635C-FDA4-4D93-BD71-E0FAE1776016Q34624315-2DD52AE7-26BE-4D2B-9D50-F4A023AAEC42Q35078360-9DD22A02-0808-4B8E-9D5E-E55E0BD68920Q35105255-0BE19DF3-1A99-434B-8488-B008839FC94BQ35232187-6D4CE4CC-CDE3-4006-A1B7-7532837C7E04Q35290066-23BDFE88-A7FB-4914-8E90-68E2275AAD4CQ36458158-D31A85E0-FC6F-41A5-AAFD-3A833FDE3826Q36460566-095B7D49-E563-4ABD-B3F1-B8214E283CEFQ36599937-B299AD80-E150-4074-B0F8-C4ABA7850E34Q36689825-69B44C97-A496-4678-8E2D-44AC3EC71739Q36751935-215637A7-F0EF-4CB0-AC09-B3C203088715Q37140623-7848BEF7-EE81-4B40-ABE3-0438DE97D3D5Q37321940-54491F60-78A3-47BB-9303-8003466E53AEQ37733556-EB406C48-2BE7-4855-8785-6614D43B333BQ37920916-3C47E0E4-59EC-4912-9887-549CCD3666D5Q37987260-6C22CEE9-12AE-4E8A-A378-4D50E03DED79Q38024409-68183BCE-16A2-43EB-9360-456108122E4DQ38042912-78248A1A-F0F6-4B7E-9DC8-59CF22B34E99Q38122721-97210776-C726-489A-AD28-6D6B412E0088Q38248275-1014EBD5-F9AC-40F4-B2F1-4DDF8FB06976Q38692296-25369AF3-1166-45D7-977B-C16C821A48B0Q38815890-BAC429BF-1C61-4EB7-B0FC-D8521938FFF2Q38821274-B5AC4A2B-1A86-4743-89DB-E12032061C91Q38855314-66DFB8B7-0C97-4D14-B29B-E8B98CBBACCCQ39846256-7CA3C428-1BBA-4681-8EFC-C81D114C3ACAQ40966305-83CC6B71-6146-47CF-A325-C5429E1E9A1DQ41540824-78C1FFF9-0ABF-4B00-A4E9-A96B43E52241Q41978073-7DE97CBB-F0A0-433F-B129-6CE87EE4DBF7Q42789355-561E970C-1A2A-4D5B-B0F2-D444A3B1DB9CQ43132024-2CB4CA16-8234-4AB4-9F67-461748EF584AQ43289038-08341157-1B8E-4E67-8A79-D2F346826FA0Q44052055-E7E60E14-780F-4696-9EFB-8E922188D102Q44306205-73287858-137D-460C-9B5E-0E9CF6D67EF9Q46729796-306C7CD6-CB3E-4750-B876-DFCCDE0700C3Q50233999-29D80D83-2248-4129-BB7F-E13CAFCD999E
P2860
The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction.
@ast
The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction.
@en
type
label
The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction.
@ast
The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction.
@en
prefLabel
The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction.
@ast
The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction.
@en
P2860
P356
P1476
The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction
@en
P2093
Andreas Kovar
Manish Gupta
P2860
P304
P356
10.1177/0091270005276847
P577
2005-09-01T00:00:00Z